Nasovac-S is developed by London School of Hygiene and Tropical Medicine.

What development phase is Nasovac-S in?

Nasovac-S is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Nasovac-S

London School of Hygiene and Tropical Medicine · FDA-approved active Biologic Quality 2/100

Nasovac-S, developed by the London School of Hygiene and Tropical Medicine, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Nasovac-S
Sponsor	London School of Hygiene and Tropical Medicine
Modality	Biologic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nasovac-S CI brief — competitive landscape report
Nasovac-S updates RSS · CI watch RSS
London School of Hygiene and Tropical Medicine portfolio CI